Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma

Xia, Jufeng; Rong, Ling; Sawakami, Tatsuo; Inagaki, Yoshiaki; Song, Peipei; Hasegawa, Kiyoshi; Sakamoto, Yoshihiro; Tang, Wei

doi:10.1016/j.biopha.2018.01.163

Cited by 32 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical trials: No data 2. Retrospective clinical data: Case series ( n = 4) of mild or severe COVID-19 pneumonia successfully treated with LPV/r + arbidol + Shufeng Jiedo Capsule (traditional Chinese medicine) [ 85 , 86 ] 3. In vivo animal or in vitro data: No data Chloroquine + LPV/r Inhibition of replication PLUS inhibition of viral entry Increased risk of QTc prolongation (potentially dangerous interaction) Inhibition of CYP3A-mediated metabolism of chloroquine by ritonavir Level of severity: Major Therapeutic advice: Monitor ECG and monitor for increased toxicity of chloroquine if used in combination.…”

Section: Search Methodologymentioning

confidence: 99%

See 1 more Smart Citation

Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents

et al. 2020

View full text Add to dashboard Cite

There is an urgent need to identify optimal antiviral therapies for COVID-19 caused by SARS-CoV-2. We have conducted a rapid and comprehensive review of relevant pharmacological evidence, focusing on (1) the pharmacokinetics (PK) of potential antiviral therapies; (2) coronavirus-specific pharmacodynamics (PD); (3) PK and PD interactions between proposed combination therapies; (4) pharmacology of major supportive therapies; and (5) anticipated drug-drug interactions (DDIs). We found promising in vitro evidence for remdesivir, (hydroxy)chloroquine and favipiravir against SARS-CoV-2; potential clinical benefit in SARS-CoV-2 with remdesivir, the combination of lopinavir/ritonavir (LPV/r) plus ribavirin; and strong evidence for LPV/r plus ribavirin against Middle East Respiratory Syndrome (MERS) for post-exposure prophylaxis in healthcare workers. Despite these emerging data, robust controlled clinical trials assessing patient-centred outcomes remain imperative and clinical data have already reduced expectations with regard to some drugs. Any therapy should be used with caution in the light of potential drug interactions and the uncertainty of optimal doses for treating mild versus serious infections. On behalf of the PK/PD of Anti-Infectives Study Group (EPASG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID); all authors are affiliated with this group.

show abstract

Section: Search Methodologymentioning

confidence: 99%

“…2. Retrospective clinical data: Case series ( n = 4) of mild or severe COVID-19 pneumonia successfully treated with LPV/r + arbidol + Shufeng Jiedo Capsule (traditional Chinese medicine) [ 85 , 86 ]…”

Section: Search Methodologymentioning

confidence: 99%

Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Combination of SFJDC with doxorubicin induced more considerable apoptosis and invasion and migration suppression [94] Dahuang zhechong pill…”

Section: Resultsmentioning

confidence: 99%

“…Recently, scholars used combination of SFJDC with doxorubicin to treat liver cancer cells and further explored the underlying mechanisms of SFJDC as well as its constituents in vitro. The data showed that the combination group induced more considerable apoptosis and invasion and migration suppression than control group by targeting NF-κB, Akt/mTOR, and mitochondrial signaling pathways [94].…”

Section: Kou Et Al Investigated the Radiosensitizing Effects Of Ultrmentioning

confidence: 98%

What Chinese Medicine Can Do for Liver Cancer?

Chen¹,

Wang²,

Feng³

2018

Liver Cancer

View full text Add to dashboard Cite

Liver cancer is an international problem, especially in Asian countries. It is because that most liver cancers are already late stage when they are diagnosed, and also most liver cancers have various previous chronic liver diseases induced by alcoholic, virus, and steatosis, etc. In recent years, laboratory and clinical studies focusing on liver cancer by Chinese medicine has been extensively studied. What Chinese medicine treatment formalities can be used in liver cancer? How Chinese medicine can be employed in treatment of liver cancer? What Chinese medicine can contribute to liver cancer? To answer these questions in this chapter, we will review and discuss treatment of liver cancer from Chinese medicine's perspective with scientific evidences as following three parts: (1) Chinese medicine as the source of discovering new treatment for liver cancer, (2) Chinese medicine as a complementary treatment of liver cancer, and (3) to discuss future research and application of Chinese medicine in liver cancer treatment.

show abstract

“…Lu et al [12], in an early overview of possible options for COVID-19 treatment, mentioned lopinavir/ritonavir, nucleoside analogues, neuraminidase inhibitors, remdesivir [13], peptide EK1 [14]), arbidol [15], RNA synthesis inhibitors (such as tenofovir disoproxil fumarate, lamivudine), anti-inflammatory drugs (such as hormones and other molecules), along with Chinese traditional medicines, such as ShuFengJieDu [16] and Lianhuaqingwen [17].…”

Section: Introductionmentioning

confidence: 99%

Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple

Spezzani

Piunno

Iselin³

2020

Swiss Med Wkly

View full text Add to dashboard Cite

Respiratory failure in COVID-19 is a common feature in fatal cases and has been considered as a failure of the immune system to control the virus. Here we report the case of COVID-19 affecting an immunocompromised women and her presumably immunocompetent spouse. A married couple (age 60 years) was simultaneously admitted to the emergency department on 10 March 2020 because of dyspnoea and fever, consistent with COVID-19. The wife (patient 1) was partially immunocompromised as a consequence of a recently started chemotherapy with fulvestrant and abemaciclid for recurring breast cancer, her husband (patient 2) had been healthy except for a history of controlled arterial hypertension. Both patients were treated with darunavir/cobicistat and hydroxychloroquine. The clinical course of the immunocompromised partner was benign, without need of intensive care. She was able to leave the hospital on day 6 after admission. In contrast, her husband needed intensive care and his recovery was slow, although eventually successful too. These findings suggest that the course of COVID-19 is not necessarily ominous in the presence of a compromised immune response and tend to reinforce the emerging therapeutic concepts of a controlled mitigation of the immune cascade following SARS CoV-2 infection.

show abstract

Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma

Cited by 32 publications

References 29 publications

Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents

Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents

What Chinese Medicine Can Do for Liver Cancer?

Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple

Contact Info

Product

Resources

About